Exploration of Potential Gut Microbiota-Derived Biomarkers to Predict the Success of Fecal Microbiota Transplantation in Ulcerative Colitis: A Prospective Cohort in Korea
1
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background/Aims: Although fecal microbiota transplantation (FMT) has been proven as one of the promising treatments for patients with ulcerative colitis (UC), potential prognostic markers regarding the clinical outcomes of FMT remain elusive. Methods: We collected fecal samples of 10 participants undergoing FMT to treat UC and those from the corresponding donors. We categorized them into two groups: responders and nonresponders. Sequencing of the bacterial 16S rRNA gene was conducted on the samples to explore bacterial composition. Results: Analyzing the gut microbiota of patients who showed different outcomes in FMT presented a distinct microbial niche. Source tracking analysis showed the nonresponder group had a higher rate of preservation of donor microbiota, underscoring that engraftment degrees are not one of the major drivers for the success of FMT. At the phylum level, Bacteroidetes bacteria were significantly depleted (p<0.003), and three genera, including Enterococcus, Rothia, and Pediococcus, were enriched in the responder group before FMT (p=0.003, p=0.025, and p=0.048, respectively). Furthermore, we applied a machine learning algorithm to build a prediction model that might allow the prediction of FMT outcomes, which yielded an area under the receiver operating characteristic (ROC) curve of 0.844. Notably, the microbiota-based model was much better at predicting outcomes than the clinical features model (area under the ROC curve=0.531). Conclusions: This study is the first to suggest the significance of indigenous microbiota of recipients as a critical factor. The result highlights that bacterial composition should be evaluated before FMT to select suitable patients and achieve better efficiency.
Abstract
Background/Aims: Although fecal microbiota transplantation (FMT) has been proven as one of the promising treatments for patients with ulcerative colitis (UC), potential prognostic markers regarding the clinical outcomes of FMT remain elusive. Methods: We collected fecal samples of 10 participants undergoing FMT to treat UC and those from the corresponding donors. We categorized them into two groups: responders and nonresponders. Sequencing of the bacterial 16S rRNA gene was conducted on the samples to explore bacterial composition. Results: Analyzing the gut microbiota of patients who showed different outcomes in FMT presented a distinct microbial niche. Source tracking analysis showed the nonresponder group had a higher rate of preservation of donor microbiota, underscoring that engraftment degrees are not one of the major drivers for the success of FMT. At the phylum level, Bacteroidetes bacteria were significantly depleted (p<0.003), and three genera, including Enterococcus, Rothia, and Pediococcus, were enriched in the responder group before FMT (p=0.003, p=0.025, and p=0.048, respectively). Furthermore, we applied a machine learning algorithm to build a prediction model that might allow the prediction of FMT outcomes, which yielded an area under the receiver operating characteristic (ROC) curve of 0.844. Notably, the microbiota-based model was much better at predicting outcomes than the clinical features model (area under the ROC curve=0.531). Conclusions: This study is the first to suggest the significance of indigenous microbiota of recipients as a critical factor. The result highlights that bacterial composition should be evaluated before FMT to select suitable patients and achieve better efficiency.
참고문헌 (56)
- Singh S, "First-and second-line pharmacotherapies for patients with moderate to severely active ulcerative colitis : an updated network meta-analysis", Clin Gastroenterol Hepatol, 18, pp.2179~2191 (2020)
- Head KA, "Inflammatory bowel disease Part 1 : ulcerative colitis : pathophysiology and conventional and alternative treatment options", Altern Med Rev, 8, pp.247~283 (2003)
- Chan SS, "Carbohydrate intake in the etiology of Crohn’s disease and ulcerative colitis", Inflamm Bowel Dis, 20, pp.2013~2021 (2014)
- Kuhnen A, "Genetic and environmental considerations for inflammatory bowel disease", Surg Clin North Am, 99, pp.1197~1207 (2019)
- Cleynen I, "Genetic factors conferring an increased susceptibility to develop Crohn’s disease also influence disease phenotype : results from the IBDchip European Project", Gut, 62, pp.1556~1565 (2013)
- Lerner A, "Aluminum is a potential environmental factor for Crohn’s disease induction : extended hypothesis", Ann N Y Acad Sci, 1107, pp.329~345 (2007)
- Chiba M, "Westernized diet is the most ubiquitous environmental factor in inflammatory bowel disease", Perm J, 23, pp.18~107 (2019)
- Lopez J, "Fecal microbiota transplantation for inflammatory bowel disease", Gastroenterol Hepatol(N Y), 12, pp.374~379 (2016)
- Emiko Mizoguchi, "Recent updates on the basic mechanisms and pathogenesis of inflammatory bowel diseases in experimental animal models", Intestinal research, 18(2), pp.151~167 (2020), 대한장연구학회[DOI]
- Hibi T, "Introduction and overview: recent advances in the immunotherapy of inflammatory bowel disease", J Gastroenterol, 38(Suppl 15), pp.36~42 (2003)
- Paramsothy S, "Specific bacteria and metabolites associated with response to fecal microbiota transplantation in patients with ulcerative colitis", Gastroenterology, 156, pp.1440~1454 (2019)
- Ng SC, "Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century : a systematic review of population-based studies", Lancet, 390, pp.2769~2778 (2017)
- Khanna S, "Changes in microbial ecology after fecal microbiota transplantation for recurrent C. difficile infection affected by underlying inflammatory bowel disease", Microbiome, 5, pp.55~ (2017)
- Kelly CR, "Update on fecal microbiota transplantation 2015 : indications, methodologies, mechanisms, and outlook", Gastroenterology, 149, pp.223~237 (2015)
- Sahil Khanna, "Management of Clostridioides difficile infection in patients with inflammatory bowel disease", Intestinal research, 19(3), pp.265~274 (2021), 대한장연구학회[DOI]
- Kanika Sehgal, "Gut microbiome and checkpoint inhibitor colitis", Intestinal research, 19(4), pp.360~364 (2021), 대한장연구학회[DOI]
- Paramsothy S, "Multidonor intensive faecal microbiota transplantation for active ulcerative colitis : a randomised placebo-controlled trial", Lancet, 389, pp.1218~1228 (2017)
- Paramsothy S, "Faecal microbiota transplantation for inflammatory bowel disease : a systematic review and meta-analysis", J Crohns Colitis, 11, pp.1180~1199 (2017)
- Allegretti J, "The current landscape and lessons from fecal microbiota transplantation for inflammatory bowel disease : past, present, and future", Inflamm Bowel Dis, 23, pp.1710~1717 (2017)
- Moayyedi P, "Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial", Gastroenterology, 149, pp.102~109 (2015)
- Costello SP, "Short duration, low intensity, pooled fecal microbiota transplantation induces remission in patients with mild-moderately active ulcerative colitis : a randomised controlled trial", Gastroenterology, 152, pp.S198~S199 (2017)
- Cammarota G, "European consensus conference on faecal microbiota transplantation in clinical practice", Gut, 66, pp.569~580 (2017)
- Bolyen E, "Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2", Nat Biotechnol, 37, pp.852~857 (2019)
- Callahan BJ, "DADA2 : high-resolution sample inference from Illumina amplicon data", Nat Methods, 13, pp.581~583 (2016)
- Quast C, "The SILVA ribosomal RNA gene database project : improved data processing and web-based tools", Nucleic Acids Res, 41(Database issue), pp.D590~D596 (2013)
- R Core Team, "R: A language and environment for statistical computing. R package version 2013:2-0", The Comprehensive R Archive Network, ~ (2013)
- Wickham H, "ggplot2", Wiley Interdiscip Rev Comput Stat, 3, pp.180~185 (2011)
- "The vegan package:community ecology package. R package version. 2013"[URL]
- Knights D, "Bayesian community-wide culture-independent microbial source tracking", Nat Methods, 8, pp.761~763 (2011)
- "BugBase predicts organism-level microbiome phenotypes" (2017)[URL]
- Schmidt TS, "Extensive transmission of microbes along the gastrointestinal tract", Elife, 8, pp.e42693~ (2019)
- Lobo JM, "AUC : a misleading measure of the performance of predictive distribution models", Glob Ecol Biogeogr, 17, pp.145~151 (2008)
- Wirbel J, "Microbiome meta-analysis and cross-disease comparison enabled by the SIAMCAT machine learning toolbox", Genome Biol, 22, pp.93~ (2021)
- Costello SP, "Effect of fecal microbiota transplantation on 8-week remission in patients with ulcerative colitis : a randomized clinical trial", JAMA, 321, pp.156~164 (2019)
- Siegmund B, "Is intensity the solution for FMT in ulcerative colitis", Lancet, 389, pp.1170~1172 (2017)
- Ishikawa D, "The microbial composition of bacteroidetes species in ulcerative colitis is effectively improved by combination therapy with fecal microbiota transplantation and antibiotics", Inflamm Bowel Dis, 24, pp.2590~2598 (2018)
- Okahara K, "Matching between donors and ulcerative colitis patients is important for longterm maintenance after fecal microbiota transplantation", J Clin Med, 9, pp.1650~ (2020)
- Ishikawa D, "Changes in intestinal microbiota following combination therapy with fecal microbial transplantation and antibiotics for ulcerative colitis", Inflamm Bowel Dis, 23, pp.116~125 (2017)
- Lee SM, "Bacterial colonization factors control specificity and stability of the gut microbiota", Nature, 501, pp.426~429 (2013)
- Coyne MJ, "A family of anti-Bacteroidales peptide toxins wide-spread in the human gut microbiota", Nat Commun, 10, pp.3460~ (2019)
- Rigottier-Gois L, "Dysbiosis in inflammatory bowel diseases : the oxygen hypothesis", ISME J, 7, pp.1256~1261 (2013)
- Henson MA, "Microbiota dysbiosis in inflammatory bowel diseases : in silico investigation of the oxygen hypothesis", BMC Syst Biol, 11, pp.145~ (2017)
- Zhu H, "Oxidative stress and redox signaling mechanisms of inflammatory bowel disease: updated experimental and clinical evidence", Exp Biol Med(Maywood), 237, pp.474~480 (2012)
- Basson AR, "Autologous fecal microbiota transplantation for the treatment of inflammatory bowel disease", Transl Res, 226, pp.1~11 (2020)
- Wilson BC, "The super-donor phenomenon in fecal microbiota transplantation", Front Cell Infect Microbiol, 9, pp.2~ (2019)
- Kalla R, "The role of autologous fecal microbiota transplantation in diversion colitis : a case report", Inflamm Bowel Dis, 25, pp.e29~e30 (2019)
- Holster S, "The effect of allogenic versus autologous fecal microbiota transfer on symptoms, visceral perception and fecal and mucosal microbiota in irritable bowel syndrome : a randomized controlled study", Clin Transl Gastroenterol, 10, pp.e00034~ (2019)
- Rossen NG, "Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis", Gastroenterology, 149, pp.110~118 (2015)
- Srivastava A, "Gut biofilm forming bacteria in inflammatory bowel disease", Microb Pathog, 112, pp.5~14 (2017)
- Stecher B, "Flagella and chemotaxis are required for efficient induction of Salmonella enterica serovar Typhimurium colitis in streptomycin-pretreated mice", Infect Immun, 72, pp.4138~4150 (2004)
- Pedraz L, "Gradual adaptation of facultative anaerobic pathogens to microaerobic and anaerobic conditions", FASEB J, 34, pp.2912~2928 (2020)
- Toiyama Y, "The expression patterns of Toll-like receptors in the ileal pouch mucosa of postoperative ulcerative colitis patients", Surg Today, 36, pp.287~290 (2006)
- Nami Y, "Probiotic properties of enterococcus isolated from artisanal dairy products", Front Microbiol, 10, pp.300~ (2019)
- Benyacoub J, "Enterococcus faecium SF68 enhances the immune response to Giardia intestinalis in mice", J Nutr, 135, pp.1171~1176 (2005)
- Rosier BT, "Isolation and characterization of nitrate-reducing bacteria as potential probiotics for oral and systemic health", Front Microbiol, 11, pp.555465~ (2020)
- Bai S, "Gut microbiotaderived inflammation-related serum metabolites as potential biomarkers for major depressive disorder", J Inflamm Res, 14, pp.3755~3766 (2021)